Literature DB >> 9712028

Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice.

Z Dai1, B T Konieczny, F K Baddoura, F G Lakkis.   

Abstract

We examined whether IL-2 regulates alloimmune responses by studying allograft survival in wild-type (IL-2+/+) and IL-2 gene-knockout (IL-2-/-) mice. The acute rejection of vascularized, cardiac allografts and the generation of allospecific CTLs were not impaired in the absence of IL-2. In contrast, blocking the B7-CD28 T cell costimulation pathway with CTLA4Ig induced long-term allograft survival (> 100 days) in IL-2+/+ recipients but failed to do so in IL-2-/- mice or in wild-type mice that had been treated with IL-2-neutralizing Ab around the time of transplantation. Allografts rejected by IL-2-/- recipients exhibited extensive mononuclear cell infiltrates despite CTLA4Ig administration. In vivo allostimulation in the absence of IL-2 led to exaggerated T lymphocyte proliferation and impaired apoptosis of activated T cells in untreated and CTLA4Ig-treated mice. These findings indicate that endogenous IL-2 is required for the induction of long-term allograft survival, and that IL-2 regulates alloimmune responses by preparing activated T lymphocytes for alloantigen-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712028

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Finally, CTLA4Ig graduates to the clinic.

Authors:  M H Sayegh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.

Authors:  Masayuki Sho; Sigrid E Sandner; Nader Najafian; Alan D Salama; Victor Dong; Akira Yamada; Koji Kishimoto; Hiroshi Harada; Isabela Schmitt; Mohamed H Sayegh
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Is transplantation tolerable?

Authors:  Terry B Strom
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 5.  Routes to transplant tolerance versus rejection; the role of cytokines.

Authors:  Patrick T Walsh; Terry B Strom; Laurence A Turka
Journal:  Immunity       Date:  2004-02       Impact factor: 31.745

Review 6.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

7.  IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice.

Authors:  Jeong-hoon Lee; Jongwon Ha; Shi-hwa Kim; Sang Joon Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

Review 8.  Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.

Authors:  Carrie Gibbons; Megan Sykes
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice.

Authors:  Julie Mangada; Todd Pearson; Michael A Brehm; Linda S Wicker; Laurence B Peterson; Leonard D Shultz; David V Serreze; Aldo A Rossini; Dale L Greiner
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

10.  Manipulating IL-2 availability amid presentation of donor MHC antigens suppresses murine alloimmune responses by inducing regulatory T cells.

Authors:  Shuzi Zhang; Hehua Dai; Ni Wan; Yolonda Moore; Zhenhua Dai
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.